MedPath
HSA Approval

KESTINE FILM-COATED TABLET 20MG

SIN15644P

KESTINE FILM-COATED TABLET 20MG

KESTINE FILM-COATED TABLET 20MG

March 12, 2019

ZUELLIG PHARMA PTE. LTD.

EURODRUG LABORATORIES SINGAPORE PTE. LTD.

Regulatory Information

ZUELLIG PHARMA PTE. LTD.

EURODRUG LABORATORIES SINGAPORE PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

TABLET, FILM COATED

**DOSAGE AND ADMINISTRATION:** For oral use. EBASTINE (Kestine®) 20 mg film-coated tablets may be taken with or without food. Tablets must be swallowed whole with a small amount of water. **Adults and children over 12 years of age**– The usual dose is 10 mg of ebastine once daily, but some patients may require a dose of 20mg once daily. **Children 12 years old and below**– The safety of ebastine film-coated tablets has not been established for children under 12 years of age. **For Elderly**– not necessary to adjust dose.**For patients with Renal Impairment**– not necessary to adjust dose.**For patients with Liver Impairment**– not necessary to adjust dose but in patients with liver failure a dose of 10 mg/day should not be exceeded.

ORAL

Medical Information

**INDICATION:** EBASTINE (Kestine®) is indicated in the treatment of allergic rhinitis (seasonal and perennial) with or without allergic conjunctivitis.

**CONTRAINDICATION:** Hypersensitivity to EBASTINE or any of the excipients.

R06AX22

ebastine

Manufacturer Information

EURODRUG LABORATORIES SINGAPORE PTE. LTD.

Industrias Farmaceuticas Almirall. S.A. (IFA)

Active Ingredients

Micronised Ebastine

20.0mg

Ebastine

Documents

Package Inserts

Kestine 20mg Film-coated Tablet PI.pdf

Approved: March 12, 2019

Download
© Copyright 2025. All Rights Reserved by MedPath
KESTINE FILM-COATED TABLET 20MG - HSA Approval | MedPath